SpringWorks TherapeuticsSWTX
SWTX
About: SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Employees: 368
0
Funds holding %
of 7,457 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
383% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 23
141% more call options, than puts
Call options by funds: $287M | Put options by funds: $119M
39% more funds holding
Funds holding: 215 [Q4 2024] → 299 (+84) [Q1 2025]
29% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 9 (+2) [Q1 2025]
11% more capital invested
Capital invested by funds: $2.92B [Q4 2024] → $3.24B (+$316M) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 86
10.86% less ownership
Funds ownership: 108.72% [Q4 2024] → 97.85% (-10.86%) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$47
2%
upside
Avg. target
$47
2%
upside
High target
$47
2%
upside
4 analyst ratings
0 positive
0%
4 neutral
100%
0 negative
0%
Guggenheim Michael Schmidt 38% 1-year accuracy 17 / 45 met price target | 2%upside $47 | Neutral Reiterated | 12 May 2025 |
HC Wainwright & Co. Robert Burns 22% 1-year accuracy 36 / 166 met price target | 2%upside $47 | Neutral Downgraded | 30 Apr 2025 |
TD Cowen Yaron Werber 50% 1-year accuracy 7 / 14 met price target | 2%upside $47 | Hold Downgraded | 29 Apr 2025 |
Barclays Peter Lawson 17% 1-year accuracy 5 / 29 met price target | 2%upside $47 | Equal-Weight Downgraded | 28 Apr 2025 |
Financial journalist opinion
Based on 18 articles about SWTX published over the past 30 days
Negative
Zacks Investment Research
1 week ago
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.
Neutral
Business Wire
2 weeks ago
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
2 weeks ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX ), relating to the proposed merger with Merck KGaA, Darmstadt, Germany.
Neutral
PRNewsWire
2 weeks ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold.
Neutral
Business Wire
2 weeks ago
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of.
Positive
Investopedia
2 weeks ago
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.
Neutral
Business Wire
2 weeks ago
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks shareholders. Halper Sadeh encourages SpringWorks shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigati.
Positive
Proactive Investors
2 weeks ago
Merck KGaA swoops for US group SpringWorks in $3.4bn deal
Germany's Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion in cash. The deal, announced on Monday, values SpringWorks at $47 a share and reflects an enterprise value of $3.4 billion after accounting for the company's cash reserves.
Positive
WSJ
2 weeks ago
Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.
Charts implemented using Lightweight Charts™